The mean duration of diabetes was 15.4 years, the mean BMI was 31.1 kg/m 2 , the mean HbA 1c was 8%, and the mean eGFR was 73.8 mL/min/1.73 m 2
Additional Benefits Beyond weight and glycemic outcomes, studies have documented significant improvements in cardiovascular risk markers, liver fat reduction in NASH, improvements in obstructive sleep apnea, and enhanced quality of life metrics
Flavors are punchy with notes of pear and apple
Research has found that BPC-157 promotes fibroblast proliferation and migration to injury sites, with fibroblasts being the primary cells responsible for producing collagen and other structural extracellular matrix proteins
Reductions in HbA 1c and body weight by gender and age Significantly greater reductions in HbA 1c were achieved by subjects treated with semaglutide than by those receiving placebo, and this decrease was consistent for both genders (ETD for semaglutide 0.5 and 1.0 mg vs placebo: 0.65% [95% CI 0.80
The FDA specifically flagged multi-dose vial dosing as a safety concern in their alerts about compounded semaglutide
